Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

Mutations in BRAF are present in the majority of patients with melanoma, rendering these tumors sensitive to targeted therapy with BRAF and MEK inhibitors. Unfortunately, resistance almost invariably develops. Recently, a phenomenon called "phenotype switching" has been identified as an escape route. By switching from a proliferative to an invasive state, melanoma cells can acquire resistance to these targeted therapeutics. Interestingly, phenotype switching bears a striking resemblance to the epithelial-to-mesenchymal-like transition that has been described to occur in cancer stem cells in other tumor types. We propose that these changes are manifestations of one and the same underlying feature, namely a dynamic and reversible phenotypic tumor cell plasticity that renders a proportion of cells both more invasive and resistant to therapy. At the same time, the specific characteristics of these tumor cell populations offer potential for being explored as target for therapeutic intervention.

[1]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[2]  E. López-Bonet,et al.  Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin) , 2012, Cell cycle.

[3]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[4]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[5]  N. Altorki,et al.  TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer , 2010, Proceedings of the National Academy of Sciences.

[6]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[7]  R. Dummer,et al.  Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. , 2013, The Journal of investigative dermatology.

[8]  Xifeng Wu,et al.  Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells , 2008, Clinical Cancer Research.

[9]  Dong Wang,et al.  Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts , 2013, Stem cell reports.

[10]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[11]  I. Mackenzie,et al.  Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. , 2011, Cancer research.

[12]  P. Bunn,et al.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma , 2007, Molecular Cancer Therapeutics.

[13]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[14]  R. Dummer,et al.  A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status , 2011, Pigment cell & melanoma research.

[15]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[16]  J. Dering,et al.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. , 2010, Neoplasia.

[17]  A. Weeraratna,et al.  The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report , 2010, Melanoma research.

[18]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[19]  M. Wicha,et al.  Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. , 2012, Molecular cell.

[20]  Stuart Thomson,et al.  Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy , 2008, Clinical & Experimental Metastasis.

[21]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[22]  Samra Turajlic,et al.  BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.

[23]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[24]  G. Cavet,et al.  Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.

[25]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[26]  Arnell Carter,et al.  The Orphan Tyrosine Kinase Receptor, ROR2, Mediates Wnt5A Signaling in Metastatic Melanoma , 2009, Oncogene.

[27]  R. Moon,et al.  WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. , 2014, The Journal of clinical investigation.

[28]  Derek C. Radisky,et al.  OTX1 expression in breast cancer is regulated by p53 , 2014, Oncogene.

[29]  M. Bittner,et al.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.

[30]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[31]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[32]  J. Haley,et al.  Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition , 2007, Molecular Cancer Therapeutics.

[33]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[34]  Max S Wicha,et al.  HER2 and breast cancer stem cells: more than meets the eye. , 2013, Cancer research.

[35]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[36]  M. Middleton,et al.  Directed phenotype switching as an effective antimelanoma strategy. , 2013, Cancer cell.

[37]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[38]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[39]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.